AKTX earnings: next report 2026-08-18, real EPS beat/miss history, analyst consensus Buy, P/E -0.01. Updated 2026-07-23.
Akari Therapeutics (AKTX) Research Hub
Akari Therapeutics (AKTX) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 11.3 USD (+6.91%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.01, market cap 0.01B. This hub links to the full technical, earnings and options research available for AKTX.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 11.3 USD (+6.91%) |
| 52-week range | 6.91 USD – 15.5 USD |
| Trend regime | Range |
| 14-day RSI | 75.8 (Overbought) |
| Trailing P/E | -0.01 |
| Market cap | 0.01B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-18 |
Available research for AKTX
Covered Call on AKTX: how it works, illustrative setup around the real 11.3 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on AKTX: how it works, illustrative setup around the real 11.3 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on AKTX: how it works, illustrative setup around the real 11.3 USD price, max profit/loss, breakeven and when to use it. Educational.
AKTX technical analysis: range, last 11.3 USD, RSI 75.8, 52w range 6.91 USD–15.5 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is AKTX in?
Akari Therapeutics (AKTX) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is AKTX in an uptrend or downtrend?
As of 2026-09-11, AKTX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is AKTX's trailing P/E ratio?
AKTX's trailing P/E is -0.01, with a market cap of 0.01B. See the earnings research page for full valuation detail.
When does AKTX next report earnings?
AKTX is next scheduled to report earnings on 2026-08-18, with a consensus EPS estimate of -1.04 USD.